Mostrar el registro sencillo del ítem
Three-year outcomes in a randomized single-blind controlled trial of intravitreal ranibizumab and oral supplementation with docosahexaenoic Acid and antioxidants for diabetic macular edema
dc.contributor.author | Lafuente, María | |
dc.contributor.author | Ortín, Lourdes | |
dc.contributor.author | Argente, María | |
dc.contributor.author | Guindo, José L. | |
dc.contributor.author | López Bernal, María D. | |
dc.contributor.author | López Román, Francisco J. | |
dc.contributor.author | Domingo, Joan Carles | |
dc.contributor.author | Lajara Blesa, Jerónimo | |
dc.date.accessioned | 2024-02-07T15:07:59Z | |
dc.date.available | 2024-02-07T15:07:59Z | |
dc.date.issued | 2019 | |
dc.identifier.uri | http://hdl.handle.net/10952/7236 | |
dc.description.abstract | Purpose: To report 3-year results of a randomized single-blind controlled trial of intravitreal ranibizumab combined with oral docosahexaenoic acid (DHA) supplementation versus ranibizumab alone in patients with diabetic macular edema. Methods: There were 26 patients (31 eyes) in the DHA group and 29 (38 eyes) in the control group. Ranibizumab (0.5 mg) was administered monthly for the first 4 months followed by a pro re nata (PRN) regimen. In the experimental group, patients received oral DHA supplementation (1,050 mg/day) (Brudyretina 1.5 g). Results: At 36 months, mean decrease of central subfield macular thickness was higher in the DHA-supplementation group than in controls (275 ± 50 mm vs. 310 ± 97 mm) with significant differences at Months 25, 30, 33, and 34. Between-group differences in bestcorrected visual acuity were not found, but the percentages of ETRDS gains .5 and .10 letters were higher in the DHA-supplementation group. Differences serum HbA1c, plasma total antioxidant capacity values, erythrocyte DHA content, and serum IL-6 levels were all significant in favor of the DHA-supplementation group. Conclusion: The addition of a high-rich DHA dietary supplement to intravitreal ranibizumab was effective to achieve better sustained improvement of central subfield macular thickness outcomes after 3 years of follow-up as compared with intravitreal ranibizumab alone. | es |
dc.language.iso | en | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Three-year outcomes in a randomized single-blind controlled trial of intravitreal ranibizumab and oral supplementation with docosahexaenoic Acid and antioxidants for diabetic macular edema | es |
dc.type | article | es |
dc.rights.accessRights | openAccess | es |
dc.journal.title | Retina, The journal of retinal and vitreous diseases | es |
dc.volume.number | 39 | es |
dc.issue.number | 6 | es |
dc.description.discipline | Medicina | es |